Stock Events

Stock Events

Protagenic Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q1 2022
Next
-2.58
-2.24
-1.91
-1.58
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-5.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBPC.MU. It's not an investment recommendation.
AMD
3
AMD
Palantir Technologies
3
PLTR
SoFi Technologies
3
SOFI
Mustang Bio
3
MBIO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap9.19B
Alkermes plc operates in the brain health area, including treatments for depression and schizophrenia, overlapping with Protagenic's focus on mental health disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.45B
ACADIA Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurotherapeutics field.
BridgeBio Pharma
BBIO
Mkt Cap15.12B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could compete with Protagenic's approach to treating mental health disorders.
Axsome Therapeutics
AXSM
Mkt Cap12.57B
Axsome Therapeutics develops novel therapies for central nervous system disorders including depression, directly competing with Protagenic's therapeutic focus.
Insmed
INSM
Mkt Cap24.19B
Insmed Incorporated works on rare diseases, including neurological disorders, potentially competing with Protagenic's research and development focus.
Neurocrine Biosciences
NBIX
Mkt Cap17.52B
Neurocrine Biosciences focuses on neurological and endocrine diseases, including treatments for mental health disorders, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, potentially competing across several of Protagenic's target areas.

About

Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Show more...
CEO
Dr. Garo H. Armen Ph.D.
Employees
1
Country
United States
ISIN
US74365N1037

Listings

MU
DE
MBPC.MU
STU
DE
MBPC.STU
MU
DE
MBP.MU
OTC Link
US
PTIX

0 Comments

Share your thoughts

FAQ

What is Protagenic Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Protagenic Therapeutics stocks are traded under the ticker MBPC.MU.
When is the next Protagenic Therapeutics earnings date?▼
Protagenic Therapeutics is going to release the next earnings report on August 18, 2026.
What is Protagenic Therapeutics revenue for the last year?▼
Protagenic Therapeutics revenue for the last year amounts to 0 EUR.
What is Protagenic Therapeutics net income for the last year?▼
MBPC.MU net income for the last year is -5.17M EUR.
How many employees does Protagenic Therapeutics have?▼
As of July 10, 2026, the company has 1 employees.
In which sector is Protagenic Therapeutics located?▼
Protagenic Therapeutics operates in the Health & Wellness sector.
When did Protagenic Therapeutics complete a stock split?▼
Protagenic Therapeutics has not had any recent stock splits.
Where is Protagenic Therapeutics headquartered?▼
Protagenic Therapeutics is headquartered in Santa Barbara, United States.